A Way Forward: Winning the War on COVID through Vaccines

11:00 AM - 1:30 PM (PDT), Tuesday, June 9, 2020
Search General Info
Search Education
Search Partnering Companies
The long-term solution to the pandemic is the availability of vaccines. Yet the development of a vaccine is complex, especially during a global pandemic of an unknown pathogen. Even so, many vaccine developers moved swiftly, using platform technologies to go from genetic sequence data to vaccine candidates in a few weeks. This three-part plenary session will focus on the novel science of vaccines in development as well as the challenges of clinical trials, manufacturing scale-up and global implementation.

This three-part plenary will be facilitated by Phyllis Arthur, Vice President, Infectious Diseases and Diagnostics Policy, BIO.

Fireside Chat with Dr. Anthony Fauci, MD, Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health
11:00 AM – 11:30 AM PDT

Moderator: Dr. Michelle McMurry-Heath, President and Chief Executive Officer, BIO

Plenary 1: Leveraging Platforms and Partnerships to Develop COVID-19 Vaccines in Record Time
11:30 AM – 12:30 PM PDT
As numerous vaccines move through clinical development there are important issues that need to be addressed. How will companies and partners conduct global clinical trials? What are the key scientific issues that must be addressed to vaccinate millions of people worldwide? This panel will discuss the complex path to clinical trials, the impact of the evolving science on their development and share their thoughts on how collaboration will bring life-saving vaccines to the world.

Moderator: Mark McClellan, MD, Director, Duke Margolis Center for Health Policy
• Gregory Glenn, MD, President, Research & Development, Novavax
• Margaret Hamburg, MD, Foreign Secretary, National Academy of Medicine
• Peter Marks, MD, PhD, Director, Center for Biologics Evaluation and Research, United States Food and Drug Administration
• Gary Nabel, MD. PhD, Chief Scientific Officer, Sanofi
• Paul Stoffels, MD, Vice Chairman of the Executive Committee, Chief Scientific Officer, Johnson & Johnson

Plenary 2: Global Solutions for Implementation: From Scale-up to Worldwide Access
12:30 PM – 1:30 PM PDT
The successful development of these vaccines is only the first part of a long-term response to the COVID-19 pandemic. In order to truly impact the pandemic, the global public health community will need to work together with public, private and NGO partners to implement the delivery of billions of doses of vaccines. To help speed eventual availability, many companies and their partners are pursing global manufacturing and distribution solutions even though these vaccines are in the early stages of development. This panel will discuss how the community can work together to ensure rapid and broad access to vaccines.

Moderator: Amanda Glassman, EVP of CGD, CEO of CGD Europe and Senior Fellow, Center for Global Development
• Stephane Bancel, Chief Executive Officer, Moderna
• Seth Berkley, MD, Chief Executive Officer, The GAVI Alliance
• Richard Hatchett, MD, Chief Executive Officer, Coalition for Epidemic Preparedness Innovation (CEPI)
• John Markels, President, Global Vaccines, Merck
• Vivien Tsu, PhD, Clinical Professor, Global Health, University of Washington
Sponsored By
Vice President, Infectious Diseases and Diagnostics Policy
Biotechnology Innovation Organization
Executive Vice President and Senior Fellow
Center for Global Deveopment
Duke University Margolis Center for Health Policy
Michelle McMurry-Heath
President and Chief Executive Officer
Biotechnology Innovation Organization
Vice President, Infectious Diseases and Diagnostics Policy
Biotechnology Innovation Organization
Chief Executive Officer
Moderna Therapeutics, Inc
Gavi, The Vaccine Alliance
Director, National Institute of Allergy and Infectious Diseases
National Institutes of Health
President, Research & Development
Novavax, Inc
Foreign Secretary
National Academies of Science
Chief Executive Officer
President, Merck Vaccines
Merck & Co.
Peter Marks
Director, Centers for Biologics Evaluation & Research
US Food & Drug Administration
Chief Scientific Officer and Senior Vice President
Sanofi Global R&D
Vice Chairman of the Executive Committee and Chief Scientific Officer
Johnson & Johnson
Clinical Professor, Global Health
University of Washington